Lexeo Therapeutics (LXEO) EBIAT: 2022-2023
Historic EBIAT for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$14.2 million.
- Lexeo Therapeutics' EBIAT rose 2.79% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 48.09% down from last year.
- According to the latest figures from Q4 2023, Lexeo Therapeutics' EBIAT is -$14.2 million, which was up 29.42% from -$20.1 million recorded in Q3 2023.
- In the past 5 years, Lexeo Therapeutics' EBIAT ranged from a high of -$13.4 million in Q2 2023 and a low of -$20.1 million during Q3 2023.
- Moreover, its 2-year median value for EBIAT was -$15.8 million (2022), whereas its average is -$16.3 million.
- Data for Lexeo Therapeutics' EBIAT shows a peak YoY increase of 2.79% (in 2023) and a maximum YoY decrease of 17.90% (in 2023) over the last 5 years.
- Quarterly analysis of 2 years shows Lexeo Therapeutics' EBIAT stood at -$14.6 million in 2022, then rose by 2.79% to -$14.2 million in 2023.
- Its EBIAT stands at -$14.2 million for Q4 2023, versus -$20.1 million for Q3 2023 and -$13.4 million for Q2 2023.